Personalized Vaccine in Treating Patients With Smoldering Multiple Myeloma

NCT03631043 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

COMPLETED

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Smoldering Plasma Cell Myeloma

Interventions

PROCEDURE: Biopsy Specimen Radiography
DRUG: Lenalidomide
BIOLOGICAL: Vaccine Therapy

Sponsor

M.D. Anderson Cancer Center